Compare AIRG & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | SER |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 56.4M |
| IPO Year | 2016 | 2024 |
| Metric | AIRG | SER |
|---|---|---|
| Price | $3.96 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $6.88 | ★ $9.50 |
| AVG Volume (30 Days) | 57.0K | ★ 66.1K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $10.21 | N/A |
| Revenue Next Year | $15.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.63 | $1.14 |
| 52 Week High | $7.66 | $4.26 |
| Indicator | AIRG | SER |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 36.22 |
| Support Level | $3.83 | $1.33 |
| Resistance Level | $5.65 | $2.13 |
| Average True Range (ATR) | 0.22 | 0.33 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 38.36 | 20.57 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.